FINCH THERAPEUTICS SOFTWARE
FINCH THERAPEUTICS TRIAL

We are more than happy that they chose CentraXX to develop a fully validated solution that meets GXP standards.

Martin Zünkeler, Managing Director and founder of KAIROS, confirms that the partnership “Finch Therapeutics is breaking new ground with the development of its microbial therapies. KAIROS has teamed up with Finch to support its growth and mission through the implementation of CentraXX to provide highly secure and available access, manage increasing workloads, monitor complex processes and gain new insights into the microbiome.

FINCH THERAPEUTICS SOFTWARE

The aim of this project is to provide a comprehensive scientific software solution that offers the “top of the class” functionality for Finch’s diverse user base. We are confident that CentraXX will enable us to meet our GMP/GCP requirements while increasing the efficiency of our activities,” said James Sigler, Vice President, Finch Therapeutics Group, Inc. The system’s ability to track the generation of samples from donation collection all the way to effective data is critical to us. “Finch is delighted to commission KAIROS to develop and implement a Manufacturing Execution System on the CentraXX platform. of Somerville, Massachusetts, USA, has completed its RFP phase and selected CentraXX from a dozen candidates for its central information management software to help manage complex clinical, biopharmaceutical and quality-related processes. KAIROS GmbH, a renowned IT company with experience in the development of software solutions for healthcare and translational biotechnological research, is pleased about a new and so far unique partnership. CentraXX CTMS is – through the use of the CentraXX Validation Kit – an essential component of a valid overall system solution for which the company is seeking FDA approval. The system is scheduled to go live in September 2018, following training sessions for Finch employees by KAIROS GmbH in the use of XML and BIRT.Īs its first step, Finch will use CentraXX CTMS for subject management (infiltration/administration), after which Finch will use CentraXX CTMS to support the SOP-controlled production of personalized – i.e.

In addition to the draw of implementing a centralized system, CentraXX also impressed Finch with its comprehensive data security, including the dedicated rights and roles concept and the ability to reliably separate personal identifying data from non-personal identifying data. CentraXX – Data protection made in Germany

FINCH THERAPEUTICS TRIAL

In the search for a suitable Clinical Trial Management System (CTMS), which replaces Finch’s current landscape of various individual systems ranging from paper-based documentation to various standard IT solutions with a central IT system, the Americans decided in favor of the KAIROS product “CentraXX CTMS”. Under the leadership of Mark Smith, the team behind the young biopharmaceutical company, some 200-strong, has attracted impressive attention worldwide through the research and development of modern therapies with the help of human intestinal microbes and successfully completed a financing call in the amount of 36 million US dollars at the beginning of 2018. 7.5 million people (especially children) die as a result.įinch Therapeutics is active in the production of biotherapeutics from stool grafts for the treatment of chronic intestinal diseases (diarrhoea). An estimated 4 billion people worldwide suffer from diarrhoea every year. 4 billion people affected and 7.5 million deaths worldwide each yearĭiarrhoea can be a symptom of many diseases (e.g. Based in Somerville, USA, Finch is working to increase knowledge in the field of diarrhoea. The biopharmaceutical company Finch Therapeutics Inc. Although medical research is currently deeply engaged in the study of human microbiomes, it is still a long way from a real understanding.

Finch therapeutics